Viridian Therapeutics, Inc.\DE (VRDN) Short term Debt (2024 - 2025)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Short term Debt of $8.4 million for Q2 2025, up 184.58% year-over-year from $3.0 million in Q2 2024, and up 184.58% quarter-over-quarter from $3.0 million in Q2 2024.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Short term Debt (2024 - 2025) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Short term Debt history runs 3 years deep, the most recent figure standing at $8.4 million for Q2 2025.
- In Q2 2025, Short term Debt rose 184.58% year-over-year to $8.4 million; the TTM figure through Jun 2025 stood at $8.4 million (up 184.58% YoY), while the FY2014 annual figure was $1.0 million, changed N/A from the prior year.
- Short term Debt for Q2 2025 stood at $8.4 million, up from $3.0 million in the prior quarter.
- The five-year high for Short term Debt was $8.4 million in Q2 2025, with the low at $3.0 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - |